Almac's Ovarian Cancer Patient Stratification Test Could Be Used to Select Treatment for Other Diseases | GenomeWeb

NEW YORK (GenomeWeb) — Almac Diagnostics has developed a microarray-based test that can be used to determine which ovarian cancer patients will have a good prognosis following chemotherapy.

The company is currently validating the test, which is run on the Affymetrix platform, with the intention of making it available for clinical use next year. Almac also believes the assay could be used to stratify patients suffering from other cancers who have undergone chemotherapy, according to Richard Kennedy, the firm's medical director.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.